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Aim. Regardless a great progress in treatment, 15 % of breast cancer cases remain lethal. One 
of the main problems in diagnosis and cure of this cancer type is its high clinical and genetic 
heterogeneity, and the identification of markers for personalized treatment is still a topical issue. 
Methods. Collection and characterization of clinical material, RNA isolation and analysis of 
the ITSN2 and TKS5 isoforms expression using real-time quantitative PCR with fluorescence 
labeled probes. Results. The reduced expression of ITSN2-S has been found in the HER2/neu-
positive tumors with poor prognosis. There was no significant difference in the expression of 
ITSN2-L and TKS5-L in the analyzed samples. Conclusions. Our study has shown a potential 
usage of the ITSN2 short  isoform (ITSN2-S) as a breast cancer prognostic marker.
K e y w o r d s: breast cancer, ITSN2, TKS5, mRNA expression analysis.
Introduction
Mammary gland malignant tumor is one of the 
most widespread among female cancer pa-
tients. According to the data of the 
GLOBOCAN project of the International 
Center for Cancer Research, 6.23 million of 
new breast cancer cases (36 % of all tumors 
in women) were discovered in the world over 
five years (from 2008 to 2012), and 15 % of 
these cases were lethal. Despite many years of 
research and extensive experience in the treat-
ment of this cancer type, one of the major 
problems in diagnosis and cure is its high 
clinical and genetic heterogeneity.
To date, from the clinical and therapeutic 
point of view, and taking into account the 
specificity of the marker genes expression, this 
group of diseases is divided into 4 main types, 
according to the expression of estrogen recep-
tors (ER), progesterone (PR), and forms of the 
epidermal growth factor receptor (HER2/neu): 
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Table 1. Breast cancer classification: histology, molecular markers and survival prognosis [2–9]
Types Subtypes Additional gene markers Prognosis
Luminal A
ER+PR+HER2/neu– 
≈40–60 %*
Low Ki-67
CK8/18+, FOXA1+, 
ESR1, GATA3, 
KRT8, KRT18, XBP1, 
FOXA1, TFF3, 
CCND1, LIV1, CK5/6–, 
EGFR–
Favorable
Luminal B
ER+PR+HER2/ 
neu+/–
≈6–20 %*
Luminal B HER2–
ER+PR+HER2/neu– 
≈15–20 %*
High Ki-67 ESR1, GATA3, 
KRT8, KRT18, XBP1, 
FOXA1, TFF3, SQLE, 
LAPTM4B, CK5/6–, 
EGFR–, TP53–
Intermediate
Luminal B HER2+
ER+PR+HER2/neu+
≈6 %*
Poor/
Intermediate
HER2 enriched
ER–PR–HER2/neu+
≈10–20 %*
CK5/6+, GRB7+, 
ERBB2, EGFR+/–TP53–
Poor
Triple negative
ER–PR–HER2/neu–
≈5–25 %*
Adenoid cystic 
carcinoma
≈1 %*
MYB-NFIB gene 
fusion
EGFR+, CK5/6+, 
CK14+, CK17+ HER1+, 
Cyclin E+, CDKN2A+, 
KRT5, CDH3, ID4, 
FABP7, KRT17, 
TRIM29, LAMC2, 
ITGB4
Favorable
Medullar carcinoma
≈2 %*
Favorable
BRCA1-associated ID4+ Poor
Basal
≈10–25 %*
BRCA1–, TP53–, 
CDKN2A+, RB1, 
FGFR2, stem cell 
markers+, CK5/6+, 
EGFR+
Poor
With low claudin
≈7–14 %*
GATA3 regulators–, cell 
adhesion genes,  
CDH1–, claudin–, 
CK5/6+/–, EGFR+/–
СD44+, SNAI3+
Poor
Metaplastic 
carcinoma
≈1 %*
GATA3 regulators–, 
cell ashesion genes, 
PIK3CA–, AKT– or 
KRAS–, EMT+, stem 
cell markers+
Intermediate
Apocrine carcinoma Intermediate
Interferon enriched
≈10 %*
STAT1+, SP110+, 
interferon-regulating 
genes+
Intermediate
* — percentage according to [2–9].
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luminal A, luminal B, HER2-enriched and 
triple negative (ER–PR–HER2/neu–) [1].
Table 1 summarizes the classification of 
breast cancer types and subtypes, depending 
on the molecular markers expression discov-
ered in recent years [2–9].
The definition of tumor aggressiveness and 
the choice of strategy for the further patients 
treatment are based on this classification. As 
can be seen from Table 1, even within the same 
type there is a certain tumor heterogeneity with 
its own prognosis and sensitivity to a particular 
treatment. Thus, for example, the triple nega-
tive type has at least eight subtypes according 
to the latest research; among them three with 
poor prognosis, three — with intermediate, and 
two — with favorable [4, 7]. Similarly, the 
tumors of luminal B type are divided into two 
subtypes: luminal B HER2/neu+ and luminal B 
HER2/neu–, which have their own treatment 
specificity. Each of the subtypes, besides three 
to four main markers, has a set of markers that 
more specifically characterize individual tu-
mors and are useful for the personalized choice 
of treatment strategy, but it is still a generaliza-
tion of data from a large number of patients. In 
practice, almost every single tumor has a spe-
cific expression pattern of the markers listed in 
Table 1. Thus, the idea of personalized treat-
ment of each case, depending on the individu-
al markers becomes more and more actual. As 
stated above, about 15 % of breast cancer 
cases are lethal, inclu ding those of incorrectly 
chosen treatment stra tegy. Significant progress 
has been made over the past few years thanks 
to the development of gene expression profiling 
technologies. Tens of new marker genes have 
been identified to characterize breast tumors. 
Thus, in experiments on gene expression anal-
ysis using microchips, it has been found that 
the ITSN2, CXCL9 and GNAI2 genes are among 
the few, the expression levels of which are 
significantly different in breast cancer tumor 
samples from patients with recurrences and in 
patients remained healthy after tumor removal 
and CMF (cyclophosphamide, methotrexate 
and fluorouracil) chemotherapy. The high 
ITSN2, CXCL9 and GNAI2 expression levels 
correlated with the absence of distant metasta-
ses for a long period of time. Besides, it has 
been found that the expression ratio of only 
two genes, CXCL9/ITSN2 may be an indepen-
dent prognostic factor to predict the absence of 
recurrences [10].
ITSN2 is an adaptor/scaffold protein [11], 
which is involved in many cellular functions, 
including clathrin-mediated endocytosis [12], 
actin cytoskeleton reorganization [13], cell 
signaling, and others [14]. Two main ITSN2 
isoforms are expressed in tissues: short 
(ITSN2-S) and long (ITSN2-L), the latter has 
three additional domains. Recently, it has been 
shown that ITSN2 interacts with WIP, the 
marker protein of the invadopodia [15, 16] 
invasive cancer cells structures responsible for 
their mobility and metastasis [17]. 
The TKS family is another recently discov-
ered family of scaffold proteins, which in-
cludes TKS4 and TKS5 that play a key role in 
the invadopodia formation [18, 19]. Likewise 
ITSN2, TKS4 and TKS5 are characterized by 
multiple alternative splicing. The TKS5 gene 
has three additional promoters which give rise 
to three short isoforms without PX domain that 
is responsible for membrane binding. The ele-
va ted mRNA level of the long TKS5 isoform 
(TKS5-L) containing all the domains, together 
with the reduced mRNA level of short isoform, 
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correlates with the progression of metastasis 
and poor prognosis for lung adenocarcinoma 
patients [20]. 
These data indicate a high potential of the 
ITSN2 and TKS5 genes and their isoforms as 
cancer prognostic markers, particularly for 
breast cancer. Therefore, we decided to inves-
tigate the mRNA expression levels of the 
ITSN2 short and long isoforms and the TKS5 
long isoform in the breast tumor samples using 
quantitative real-time PCR to evaluate the pos-
sibility of their use as prognostic markers for 
the breast cancer.
Materials and Methods
Total RNA isolation from breast tumor sam-
ples. Breast tumor samples were obtained from 
the National Cancer Institute, frozen in liquid 
nitrogen immediately after surgery and stored 
at –80°C. Total RNA was isolated from 0.2–
0.9 g tissue by guanidinium isothiocyanate 
method using the innuSOLV reagent (Analityk 
Jena) in accordance with the manufacturer’s 
recommendations. Clinical information on the 
obtained samples is presented in Table 2.
cDNA synthesis. 5 μg of total RNA were 
pre-treated with DNase I (Fermentas), accord-
ing to the manufacturer’s recommendations, 
to remove residues of genomic DNA. After 
that, cDNA synthesis was performed in 20 μl 
according to the manufacturer’s recommenda-
tions. The cDNAs were stored at –20°C.
PCR with fluorescence labeled probes. 
PCR was performed in 25 μl of mixture con-
taining 0.2 μM of each specific primer and 
0.1 μM Taq-Man probe, 1.5 mM MgCl2, 
0.2 mM dNTP, 2.5 units Taq DNA polymerase 
(Fermentas) and the corresponding buffer. 
Amplification was performed under the fol-
lowing conditions: denaturation — +94°С, 
15 s (in the first cycle — 2 min); the time and 
temperature of the primers reassociation and 
synthesis were combined: +60°C 1 min, for 
50 cycles. Each sample was analyzed in trip-
licate. PCR was performed on iQ5 BioRad. 
The TBP gene was selected as a reference 
based on the analysis of literature sources that 
showed its appropriateness as a control for the 
genes expression analysis in breast cancer 
[21–23]. Primers and probes used for PCR: 
(For.TBP 634-654 5’gtgcccgaaacgccgaatata3’, 
Table 2. Clinical information of tumor samples 
included in the study
Histological type of tumor Sample number
Invasive lobular carcinoma 44
Invasive tubular carcinoma 4
Invasive тubulolobular carcinoma 8
Invasive undifferentiated carcinoma 1
TNM classification (tumor, nodus and metastasis)
T1 17
T2 40
N0 40
N1 9
N2 8
M0 56
M1 1
Differentiation level (G)
G1 13
G2 35
G3 8
G4 1
Receptor status
ЕR+PR+HER2/neu– 31
ER–PR–HER2/neu– 11
ER+PR+HER2/neu+ 8
ER–PR–HER2/neu+ 7
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Taq-Man probe TBP 655-676 5’ (FAM)
atcccaagcggt (BHQ1)ttgctgcggt3’, Rev.TBP 
708-688 5’ccgtggttcgtggctctctta3’); (For.
ITSN2-S 3798-3821 5’cgttaagatgacgacagact-
caga3’, Taq-Man probe ITSN2-S 3820-3844 
5’(FAM)cagcacaccact (BHQ1)gttgacttggatc3’, 
Rev.ITSN2-S 3866-3845 5’attgtgtccagggtttg-
cagat3’); For.ITSN2-L 4324-4345 5’cgc-
tacccactgctcatcagaa3’, Taq-Man probe 
ITSN2-L 4362-4385 5’(FAM)cccggagagccat 
(BHQ1)gcagaccattc3’, Rev.ITSN2-L 4382-
4403 5’agggccagctttagggaggaat3’; TKS5 For.
TKS5-L 239-262 5’tgactccacctcccagactatcta3’, 
Taq-Man probe TKS5-L 354-379 5’ (BHQ2)at
ccccttcctcccaggcaagatcct(ROХ)3’, Rev.
TKS5-L 407-431 5’gatgggcttcagtctcttcacagct3’. 
The primers nucleotide positions correspond 
to the TBP cDNA with the GenBank accession 
number NM_006277, the human ITSN2 long 
and short isoforms — NM_147152 and 
NM_001172085.1 respectively, TKS5 — 
NM_014631. 
Real time PCR results calculation. The fol-
lowing formula was used to calculate PCR 
results: Exp = Etarget–Ct(target)/Eref –Ct(ref), where 
Etarget — the PCR efficacy for the target gene, 
Eref – the PCR efficacy for the reference gene, 
Ct(target) — mean cycle value for the target gene, 
Ct(ref) — mean cycle value for the reference 
gene. The PCR efficacy was determined using 
the “R” software. Fluorescence values in the 
interval between 10 and 35–40 PCR cycles 
were entered to the program, resulting in an 
indicator of the efficacy of each individual 
PCR reaction  The cycle values for the target 
and reference genes were determined as the 
point of intersection of the fluorescence curves 
with the threshold, above which the fluores-
cence value is considered significant. The 
threshold level was set the same for all ex-
periments at 100 RFU. Statistical processing 
of the PCR data was carried out with Statistica 
v.8.0 software using the ANOVA method with 
Fisher’s criterion.
Results and Discussion
ITSN2 mRNA expression analysis in breast 
cancer samples by quantitative RT-PCR. Specht 
and co-workers [10] have demonstra ted with 
quantitative RT-PCR that high ITSN2 mRNA 
levels in the surgically removed breast tumor 
samples correlated with the absence of distant 
metastases in patients for a long period of time, 
but they did not verify possible variations in 
the mRNA expression of ITSN2 isoforms. 
We have conducted such analysis on the 
tumor samples of various stages obtained from 
the National Cancer Institute. Table 2 shows 
the tumor data of patients whose samples were 
analyzed in this study. These samples were 
divided into three groups. The first group in-
cluded [the] tumors with favorable/intermedi-
ate prognosis that had the receptor status 
ЕR+PR+HER2/neu–, or luminal A type. The 
second group included the samples with triple 
negative status (ER–PR–HER2/neu–). This 
group was the most heterogeneous, however, 
the majority of tumors with this diagnosis have 
a poor survival prognosis (Table 1) [4]. The 
third group united the tumors of luminal B type 
and HER2/neu-enriched type, the receptor 
status of which was respectively ЕR+/–PR+/–
HER2/neu+. Patients with these tumors had 
a poor survival prognosis.
The total ITSN2-L and ITSN2-S mRNA 
content in tumor samples with receptor status 
ЕR+/–PR+/–HER2/neu+was significantly lower 
(p = 0.043) than in tumors with triple negative 
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receptor status, and counted 1.17–5.11 a.u. 
(median — 2.16 a.u.) against 1.62–7.7 a.u. 
(median — 2.89 a.u.). The expression level of 
two ITSN2 isoforms in the ЕR+/–PR+/–HER2/
neu+ tumors was also lower than in tumors of 
patients with a favorable prognosis 
ЕR+PR+HER2/neu–: 0.97–7.39 a.u. (median — 
3.69 a.u.) (Fig. 1A).
Significant difference  in the expression 
levels of the individual ITSN2 isoforms in dif-
ferent analyzed tumor groups were detected 
only for ITSN2-S. The lowest ITSN2-S mRNA 
content was detected in HER2/neu-positive 
tumors (0.38–2.0 a.u., median — 0.69 a.u.); 
the highest — in tumors with triple negative 
receptor status (0.57–5.17 a.u., median — 
2.21 a.u.) (Fig. 1B). There were no diffe ren ces 
in the ITSN2-L amount in the studied tumor 
groups (Fig. 1C). The ITSN2-S/ITSN2-L ratio 
reflects the overall picture of the study. The 
lowest ratio was observed in HER2/neu-posi-
tive tumors compared to tumors with triple 
negative receptor status (Fig. 1D).
We have also compared the levels of ITSN2 
isoforms mRNA expression in the tumors of 
patients younger or older than 55 years with 
Fig. 2. The relative ITSN2-S (A, C) and ITSN2-L (B, D) mRNA content in breast tumor samples from patients of dif-
ferent age (A, B) with or without metastases in lymph nodes (C, D).
Fig. 1. The relative ITSN2-S and ITSN2-L mRNA content in breast tumor samples with different receptor status. 1 — 
ER+PR+HER2/neu–; 2 — ER–PR–HER2/neu–; 3 — ER+/–PR+/–HER2/neu+; A — ITSN2-S and ITSN2-L together; B — 
ITSN2-S; C — ITSN2-L; D — ITSN2-S/ITSN2-L ratio; * — р < 0.05.
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the presence or absence of metastases in the 
lymph nodes, which is also a criterion for tumor 
aggressiveness, but there was no correlation of 
the ITSN2 isoforms mRNA content with the 
patient age or the presence of metastases in the 
lymph nodes (Fig. 2). We have also confirmed 
the ITSN2-S and ITSN2-L expression on the 
protein level (Fig. 3). The Western blot results 
reflect the general trend that every individual 
tumor has its own expression pattern.
Summarizing all data, we presume that the 
short ITSN2 isoform can be considered as one 
of the potential prognostic markers for patients 
with breast cancer. Our results have demon-
strated that it is the short ITSN2 isoform that 
reduces its expression in tumor samples with 
poor prognosis, which in turn leads to a de-
crease in total ITSN2 levels as found by Specht 
and co-workers [10]. These results were ex-
pected, since it is the long ITSN2 isoform that 
has the guanosine-metabolic activity and takes 
part in the actin cytoskeleton reorganization, 
which in turn is an important condition for 
cancer metastasis [14, 18].
TKS5 long isoform mRNA expression anal-
ysis in breast cancer samples by quantitative 
RT-PCR. TKS5, a member of the TKS family, 
is a necessary component for the formation of 
invasive cancer cell structures - invadopodia 
[18]. The mRNA of the TKS5 gene undergoes 
a number of alternative splicing events that 
affect the structure of the final protein mole-
cule. Expression of the longest of these iso-
forms (TKS5-L), which has a membrane phos-
phatidylinositol phosphates-binding domain, 
correlates with lung adenocarcinoma metasta-
sis [20]. Therefore, we have chosen to analyze 
its expression in the breast tumor samples. To 
compare the TKS5-L mRNA expression, we 
have divided breast tumor samples into two 
groups: the first contained 10 tumor samples 
with ER+PR+HER2/neu– receptor status and 
had a favorable prognosis; the second group 
contained 10 tumor samples with ER+/–PR+/–
HER2/neu+ receptor status and had a poor 
prognosis. The real-time PCR results have 
shown that TKS5-L did not significantly alter 
its expression in breast cancer tumors either 
with favorable (ER+PR+HER2/neu–) or with 
unfavorable (ER+/–PR+/–HER2/neu+) prognosis 
(Fig. 4). 
Conclusions
We have demonstrated a decrease in 
the ITSN2 mRNA expression in breast tumor 
Fig. 4. The relative TKS5-L mRNA content in breast tu-
mor samples. 1 — ER+PR+HER2/neu–; 2 — ER+/–PR+/–
HER2/neu+.
Fig. 3. Western blot analysis of ITSN2 protein expression in 
breast tumor samples. Actin was used as a loading control.
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samples with poor survival prognosis (ЕR+/–
PR+/–HER2/neu+) which is due to a decrease 
of the short ITSN2 isoform (ITSN2-S) 
amount. Thus, the  ITSN2-S mRNA expression 
can be used as a one of the prognostic markers 
for breast cancer. There were no significant 
differences in the ITSN2-L and TKS5-L ex-
pression in the analyzed tumor samples.
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Експресія ITSN2 та TKS5 у різних підтипах 
раку молочної залози
С. В. Кропивко, Л. О. Циба, О. В. Новохацька, 
Я. M. Немеш, Л. А. Сивак, Т. Є. Тарасенко, 
О. М. Грабовий, А. В. Риндич
Мета. Незважаючи на значний прогрес у лікуванні, 
15 % випадків захворювання на рак молочної заози 
залишаються летальними. Однією з головних проблем 
у діагностиці та лікуванні цього типу раку є його ви-
сока клінічна та генетична гетерогенність, тому іден-
тифікація маркерів для персоналізованої терапії є ак-
туальною проблемою. Методи. Збір та характеристи-
ка клінічного матеріалу, ізоляція РНК та аналіз екс-
пресії ізоформ ITSN2 та TKS5, використовуючи кіль-
кісну ПЛР в реальному часі з флюоресцентно 
міченими зондами. Результати. Нами було виявлено, 
що ITSN2-S знижує свою експресію в HER2/neu-
позитивних пухлинах з поганим прогнозом. Не було 
відмічено істотної різниці в експресії ITSN2-L і TKS5-L 
в проаналізованих зразках. Висновки. В даній роботі 
продемонстровано потенційну можливість викорис-
тання короткої ізоформи ITSN2 (ITSN2-S) як прогнос-
тичного маркера раку молочної залози.
К л юч ов і  с л ов а: рак молочної залози, ITSN2, 
TKS5, аналіз експресії мРНК.
Экспрессия ITSN2 и TKS5 в различных 
подтипах рака молочной железы
С. В. Кропивко, Л. А. Цыба, О. В. Новохацкая, 
Я. M. Немеш, Л. А. Сивак, Т. Е. Тарасенко, 
А. Н. Грабовой, А. В. Рындич
Цель. Несмотря на значительный прогресс в лечении, 
15 % случаев рака молочной железы остаются леталь-
ными. Несмотря на многолетние исследования, одной 
из главных проблем в диагностике и лечении этого 
типа рака является его высокая клиническая и генети-
ческая гетерогенность, поэтому идентификация мар-
керов для персонализированной терапии является 
актуальной проблемой. Методы. Сбор и хараткери-
стика клинического материала, изоляция РНК и анализ 
экспрессии изоформ ITSN2 и TKS5, используя количе-
ственную ПЦР в реальном времени с флюоресцентно 
мечеными зондами. Результаты. Нами было выявле-
но, что ITSN2-S снижает свою экспрессию в HER2/
neu-позитивных опухолях с плохим прогнозом. Не 
было отмечено существенной разницы в экспрессии 
ITSN2-L и TKS5-L в проанализированных образцах. 
Выводы. В данной работе продемонстрировано по-
тенциальную возможность использования короткой 
изоформы ITSN2 (ITSN2-S) как прогностического мар-
кера рака молочной железы.
К л юч е в ы е  с л ов а: рак молочной железы, ITSN2, 
TKS5, анализ экспрессии мРНК.
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